FDA Approves Simtriyo: What Parents Should Know About the New ADHD Medication
The U.S. Food and Drug Administration has approved a new medication called Simtriyo® (centanafadine) for treating attention-deficit/hyperactivity disorder, commonly known as ADHD.
Simtriyo is approved for adults and for children ages 6 and older who weigh at least 44 pounds. It is a once-daily, extended-release capsule and is expected to become available after the medication completes the required federal scheduling process.
For families whose children struggle with attention, organization, impulsivity, or completing schoolwork, this approval provides another treatment option to discuss with a qualified healthcare provider.
What Makes Simtriyo Different?
ADHD is connected to the way certain chemical messengers, called neurotransmitters, work in the brain. Many existing ADHD medications primarily affect dopamine and norepinephrine.
Simtriyo is different because it affects three neurotransmitters:
Dopamine, which is involved in motivation and reward
Norepinephrine, which supports attention and alertness
Serotonin, which is connected to mood and emotional regulation
Simtriyo is the first FDA-approved ADHD medication classified as a norepinephrine, dopamine, and serotonin reuptake inhibitor, or NDSRI. It is also considered a central nervous system stimulant.
This new approach may give doctors another option when selecting an ADHD treatment based on an individual student’s needs.
Who Is Simtriyo Approved For?
Simtriyo is approved to treat ADHD in:
Children ages 6 and older who weigh at least 44 pounds
Teenagers
Adults
It is not recommended for children younger than 6. It is also not recommended for children who weigh less than 44 pounds because there is not enough safety information for that group and there may be a greater risk of weight loss.
What Did the Clinical Studies Find?
The FDA’s approval was supported by four Phase 3 clinical studies involving children, teenagers, and adults with ADHD.
During these studies, participants who received Simtriyo showed greater improvement in ADHD symptoms than participants who received a placebo. Improvements were reported as early as the first week of treatment.
Research also explored areas of executive functioning, including:
Managing time
Planning and prioritizing
Starting and completing tasks
Using working memory
Managing emotions
These skills can have a major effect on a student’s ability to follow instructions, keep track of assignments, prepare for tests, and complete schoolwork independently.
However, every person responds to ADHD medication differently. A medication that helps one student may not be the right choice for another.
What Are the Possible Side Effects?
The side effects reported during clinical studies varied by age.
Commonly reported side effects included:
Decreased appetite
Headache
Nausea
Rash
Stomach pain
Vomiting
Difficulty sleeping
Dry mouth
Diarrhea
Parents should discuss potential benefits, side effects, existing health conditions, and other medications with their child’s healthcare provider.
Simtriyo also carries serious FDA warnings. Pediatric patients taking the medication must be closely monitored for suicidal thoughts or behaviors. Because Simtriyo is a stimulant, it also has the potential for misuse, abuse, and addiction. Families should follow their provider’s instructions for taking, storing, and disposing of the medication.
Parents should review the complete prescribing and safety information with a doctor or pharmacist before their child begins any new medication.
Medication Is Only One Part of ADHD Support
Medication may help reduce certain ADHD symptoms, but it does not automatically teach a student how to organize assignments, manage time, study effectively, or work through a difficult academic subject.
The Centers for Disease Control and Prevention explains that ADHD treatment often includes a combination of medication and behavioral support, depending on the child and family. Treatment plans should also be monitored and adjusted when necessary.
Students with ADHD may also benefit from:
Predictable routines
Clearly divided assignments
Visual schedules and checklists
Short, focused work periods
Regular movement breaks
Positive reinforcement
Individualized academic instruction
Support with organization and executive functioning
How Individualized Tutoring Can Help
At Thorup Tutoring, we understand that students with ADHD do not all learn in the same way. Our tutors provide personalized, one-on-one instruction based on each student’s academic needs, learning style, strengths, and challenges.
Individual tutoring can help students:
Break large assignments into manageable steps
Develop stronger study routines
Improve reading, writing, and math skills
Prepare for tests without becoming overwhelmed
Strengthen organization and time-management habits
Build confidence through consistent progress
Thorup Tutoring has more than 35 years of experience helping students, including students with ADHD, learning disabilities, and other challenges that can affect learning.
What Parents Should Do Next
The approval of Simtriyo gives families and healthcare providers another possible ADHD treatment option. It does not mean that every child with ADHD should take it or that families should change an existing treatment plan.
Parents who have questions about Simtriyo should speak with their child’s pediatrician, psychiatrist, or another qualified healthcare professional. Never begin, stop, or change an ADHD medication without medical guidance.
If your child also needs personalized academic support, Thorup Tutoring is here to help. Contact us to learn more about our one-on-one and online tutoring options.
This article is provided for general educational purposes only. Thorup Tutoring does not provide medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding ADHD medications and treatment decisions.
Sources
U.S. Food and Drug Administration: Novel Drug Approvals for 2026
Understood.org: “FDA Approves Simtriyo (centanafadine), a ‘First of Its Kind’ ADHD Medication”
Centers for Disease Control and Prevention: ADHD in Children
Simtriyo prescribing and safety information
Comments